(You can read the full research report on AbbVie here >)Ībbott shares have declined -11.7% over the past year against the Zacks Medical - Products industry's decline of -44.5%. Increasing competition from newer therapies is hurting Imbruvica's sales. However, there are concerns about long-term sales growth once Humira generics enter the U.S. Allergan's acquisition has diversified AbbVie's revenue base into new therapeutic areas, enhancing its long-term growth potential. It has several early/mid-stage candidates that have blockbuster potential. Skyrizi and Rinvoq are going strong, bolstered by approval in new indications. It has several new drugs in its portfolio, which have the potential to drive revenues once Humira loses U.S. +4.9%), reflecting the company's successful label expansion of its cancer drugs, Imbruvica and Venclexta. (You can read the full research report on JPMorgan Chase here >)ĪbbVie shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+24.0% vs. Opening new branches, strategic buyouts/investments and global expansion and digitization initiatives are likely to keep aiding the top line. However, higher interest rates and growth in loan demand are expected to result in a robust improvement in net interest income (NII). Notably, given the possibility of an economic downturn and to meet higher capital requirements, the bank has suspended buybacks. Moreover, steadily rising operating expenses remain a key near-term headwind. The company's capital markets business and higher mortgage rates are likely to make fee income growth challenging due to the uncertain macroeconomic environment. JPMorgan Chase shares have declined -18.3% over the past year against the Zacks Banks - Major Regional industry's decline of -8.8%. You can see all of today's research reports here > These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. Today's Research Daily features new research reports on 12 major stocks, including JPMorgan Chase & Co., AbbVie Inc. The Zacks Research Daily presents the best research output of our analyst team. Here are highlights from Thursday’s Analyst Blog: Top Analyst Reports for JPMorgan, AbbVie and Abbott ABBV, Abbott Laboratories ABT, Intuit Inc. Stocks recently featured in the blog include: JPMorgan Chase & Co. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Chicago, IL – Aug– announces the list of stocks featured in the Analyst Blog.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |